Overview

Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant

Status:
Terminated

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to determine if preemptive therapy with oral valganciclovir is as effective as intravenous ganciclovir in clearing cytomegalovirus (CMV) viremia as determined by quantitative CMV polymerase chain reaction (PCR) assay in patients who have undergone bone marrow or peripheral blood stem cell transplant.

Phase:

Phase 3

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

Ganciclovir
Ganciclovir triphosphate
Valganciclovir